Distribution Partnership between TRB Chemedica UK and Usono
The field of musculoskeletal and sports medicine is evolving rapidly. Clinical decision‑making is increasingly shifting from static assessment toward functional insight: how does a patient move, how do tissues behave under load, and what does that mean for recovery and performance? Driven by this shared vision, TRB Chemedica UK and Usono have entered a distribution partnership for the UK market.
Who are TRB Chemedica UK?
TRB Chemedica UK are part of the TRB Chemedica International group, a Swiss, family‑owned healthcare group with more than 30 years of experience in developing and marketing research‑led pharmaceutical products and medical devices. Established in 2002, TRB Chemedica UK specialises in musculoskeletal medicine, sports medicine, orthopaedics, ophthalmology and ultrasound.The company works closely with both NHS and private healthcare professionals and is widely recognised for its strong scientific foundation, long‑term partnerships and patient‑centred innovation. In the UK, TRB Chemedica is well known for established products such as OSTENIL®, as well as for its thoughtful approach to introducing complementary technologies, including advanced ultrasound solutions that add real clinical value.
How the Collaboration Began
The first in-person meeting between Ben Taylor Dingwall, Managing Director at TRB Chemedica UK, and Victor Donker, CEO of Usono, took place at the Sports Medicine Conference 2024 at the Emirates Stadium in London (home to Arsenal FC), following an initial connection on LinkedIn. What began as a professional exchange quickly revealed a strong strategic alignment between the two organisations.
Usono’s innovative approach to dynamic ultrasound, combined with TRB Chemedica UK’s strong reputation and established network within the UK healthcare landscape, made a collaboration feel both logical and inevitable. As TRB Chemedica UK continued to grow its presence in ultrasound through solutions such as Clarius and Mindray, Usono added an additional functional depth that clearly aligns with the company’s long‑term strategy.
The Strategic Rationale Behind the Partnership
At the heart of this collaboration lies clear strategic and clinical alignment. Both organisations share a belief that innovation only delivers value when it is scientifically credible, clinically relevant and practically applicable.Rather than focusing on rapid or purely commercial expansion, TRB Chemedica UK and Usono priorities responsible market development, supporting clinicians with technologies that genuinely enhance understanding and decision‑making. This shared philosophy makes Usono a natural and credible partner within TRB Chemedica UK’s approach to introducing new technologies to the UK market.
Ben Taylor Dingwall, Managing Director at TRB Chemedica UK: “After keeping a close eye on Usono and Victor since first meeting back in 2024, it became clear to me that their advancements and innovation around dynamic ultrasound was something I wanted to be a part of. Since diving into the world of ultrasound with Clarius a few years ago, we’ve since expanded with the Mindray Magic Series portable machines and a number of successful educational workshops which allows our customers to refine their skills and gain exposure to new technologies. The network we bring, along with the innovative products developed by Usono, make this an obvious partnership. One that compliments and elevates our current offering perfectly. I’m very excited to get to work and give ProbeFix the exposure it demands".
Why Usono Fits the Vision of TRB Chemedica UK
Usono complements TRB Chemedica UK’s established musculoskeletal portfolio by addressing an evolving clinical need, particularly within sports medicine and rehabilitation, where understanding movement and tissue behaviour in real‑world conditions is increasingly important.While traditional imaging often remains static, Usono’s dynamic ultrasound technology enables clinicians to assess function and movement in ways that reflect how patients actually load and use their bodies. This aligns strongly with TRB Chemedica UK’s vision of delivering sustainable, clinically meaningful solutions that support diagnosis, rehabilitation and long‑term patient outcomes.
A Shared Vision for Sports Medicine and Innovation
Both organisations share a vision of sports medicine that is more functional, data‑informed and patient‑specific. Across modern musculoskeletal care, there is growing recognition that imaging, diagnosis and rehabilitation must move beyond structure alone and better reflect function.The next level of sports medicine lies in integrating imaging more closely with clinical decision‑making and rehabilitation processes. Dynamic ultrasound plays a vital role in this evolution by providing insight into movement, loading and adaptation. Together, TRB Chemedica UK and Usono aim to support care pathways that enable truly personalised, movement‑aware treatment strategies.
Bringing Innovation into Everyday Clinical Practice
The strength of this partnership lies at the intersection of technological innovation and effective clinical adoption. Usono brings a genuinely differentiated and forward‑thinking dynamic ultrasound solution. TRB Chemedica UK contributes deep clinical relationships, market insight and a proven track record of supporting education and evidence‑based implementation.Through this collaboration, Usono’s technology is positioned not as a standalone product, but as part of a broader, integrated musculoskeletal ecosystem, supported by training, education, and real‑world clinical use cases. This ensures that innovation is not only introduced but meaningfully embedded into everyday musculoskeletal and sports medicine practice.
Victor Donker, CEO at Usono: “Having met Ben in person, connecting virtually and learning more about TRB has given me a lot of confidence in a great collaboration. The strength of the international parent company and the local entrepreneurial spirit show a perfect mix to bring our dreams and ProbeFix to life in the UK market. Over a longer period of time, I’ve seen and heard good things about the UK organisation in regards to education and their approach to the market. I’m really happy to bring our cultures and products together in the UK. After a great kickoff at Isokinetic in Athens, I’m looking forward to many other events in the near future".
What This Means for UK Healthcare Professionals
For healthcare professionals in the United Kingdom, this collaboration provides direct access to innovative dynamic ultrasound technology, delivered through a trusted UK partner with a deep understanding of musculoskeletal and sports medicine practice.Through TRB Chemedica UK, clinicians benefit from:
- Local clinical and commercial support
- Education and training focused on practical implementation
- Guidance on integrating dynamic ultrasound into assessment, rehabilitation and return‑to‑play decision‑making
Rather than adding another isolated tool, the partnership offers a clinically relevant, evidence‑informed solution that enhances understanding of movement, supports personalised rehabilitation strategies and ultimately helps patients return safely and confidently to the activities that matter most to them.
We’re both excited for what’s ahead!
